Table 1 Baseline characteristics of patients stratified by nodal status in the postprostatectomy specimen.

From: Neutrophil-to-lymphocyte ratio predicts nodal involvement in unfavourable, clinically nonmetastatic prostate cancer patients and overall survival in pN1 patients

Variable

Overall

pN0

n = 174 (84.88%)

pN1

n = 31 (15.12%)

p

PSA (ng/mL, mean/IQR)

19.05/9.5

17.26/8.8

29.23/16.20

0.0015

cT (n,%)

cT1

52 (26.40%)

46 (27.88%)

6 (19.35%)

0.18

cT2

140 (71.07%)

116 (70.30%)

23 (74.19%)

 

≥ cT3

5 (2.54%)

3 (1.82%)

2 (6.45%)

 

Biopsy ISUP grade group (n, %)

1

41 (20.10%)

35 (20.35%)

5 (16.13%)

0.0123

2

62 (30.39%)

58 (33.72%)

4 (12.90%)

 

3

40 (19.61%)

33 (19.19%)

7 (22.58%)

 

4

41 (20.10%)

34 (19.77%)

7 (22.58%)

 

5

20 (9.80%)

12 (6.98%)

8 (25.81%)

 

NLR (mean/IQR)

3.66/1.92

3.86/1.85

2.53/1.22

0.0025

NER (mean/IQR)

1.23/0.53

1.26/0.57

1.01/0.38

0.0568

PLR (mean/IQR)

134.13/59.31

136.28/59.22

123.42/53.60

0.07

SII (mean/IQR)

760.81/436.36

791.65/454.95

586.42/347.53

0.0047

Age (years, mean/IQR)

65/7

65/8

64/5

0.34

Prostatectomy ISUP grade group (n, %)

1

13 (6.34%)

11 (6.32%)

2 (6.45%)

< 0.0001

2

58 (28.29%)

58 (33.33%)

0 (0%)

 

3

49 (23.90%)

45 (25.86%)

4 (12.90)

 

4

48 (23.41%)

36 (20.69%)

12 (38.71%)

 

5

37 (18.05%)

24 (13.79%)

13 (41.94%)

 

pT (n, %)

pT2

91 (44.39%)

87 (50%)

4 (12.90%)

< 0.0001

pT3

112 (54.63%)

87 (50%)

25 (80.65%)

 

pT4

2 (0.98%)

0

2 (6.45%)

 

EPE (n,%)

114 (55.61%)

87 (50%)

27 (87.10%)

< 0.0001

SVI (n,%)

51 (24.76%)

30 (17.24%)

21 (67.74%)

< 0.0001

PSM (n,%)

78 (38.06%)

58 (33.33%)

20 (64.52%)

0.0021

LRP (n,%)

35 (17.00%)

32 (18.39%)

3 (9.68%)

0.30

  1. cT clinical staging, EPE extracapsular extension, IQR interquartile range, LRP laparoscopic radical prostatectomy, NER neutrophil-to-erythrocyte, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, pN pathological nodal staging, PSA prostate-specific antigen (ng/mL), PSM positive surgical margins, pT pathological local staging, SII systemic immune-inflammation index, SVI seminal vesicles involvement.